HUB Organoids specializes in advanced organoid technology that enables the creation of patient-derived organoids, which are miniature, functional replicas of human organs. This innovative approach allows researchers and pharmaceutical companies to predict patient responses to treatments more accurately than traditional methods, such as animal models or cell lines. By utilizing these organoids, HUB provides a platform for preclinical drug testing, enabling drug developers to stratify patient populations, gauge drug efficacy, and discover novel biomarkers. Their technology is particularly impactful in various therapeutic areas, including oncology, immuno-oncology, inflammatory diseases, genetic diseases, and toxicology.

The company has received recognition for its contributions to drug development, notably being awarded the 2024 Frost & Sullivan Technology Innovation Leadership Award. HUB Organoids' proprietary technology not only enhances the accuracy and efficiency of drug discovery but also supports personalized medicine initiatives by allowing for targeted clinical trials. Their services include custom model and assay development, as well as licensing opportunities for their organoid technology, which collectively aim to bridge the gap between laboratory research and clinical applications, ultimately improving patient care and therapeutic outcomes.

Netherlands

HUB Organoids (HUB) is the global leader in the field of adult stem cell-derived organoids.
HUB´s Organoid Technology represents a paradigm shift for drug discovery and development, preclinical patient stratification, predictive diagnostics, personalized medicine, clinical trials, regenerative medicine, and companion diagnostics.
HUB offers licenses to its proprietary technology and provides services its organoid biobank.

HUB Organoids

Company Details